Malaria Consortium (MC) is one of the world's leading non-profit organizations dedicated to improving health and saving lives in communities affected by malaria and related inequities in Africa and Southeast Asia. With over 20 years of proven impact, the organization works with governments, academic institutions, local and international organizations to deliver scalable, locally led health solutions grounded in research and evidence to strengthen health systems, inform policy and derive sustainable impact through strategic partnerships and organizational excellence.
The SARMAAN II Project, an acronym for Safety and Antimicrobial Resistance of Mass Administration of Azithromycin among Children 1-59 Months in Nigeria is a large-scale initiative aimed at evaluating the safety and impact of azithromycin mass drug administration (MDA) on antimicrobial resistance and child mortality. The project has both an intervention and a research component, which will be implemented across ten states in Nigeria: Sokoto, Kano, Katsina, Kebbi, Kaduna, Jigawa, Zamfara, Bauchi, Gombe and Adamawa. The research component will be led by the Nigeria Institute of Medical Research (NIMR) in collaboration with the Federal and State Ministries of Health, national agencies such as Nigeria Centre for Disease Control and Prevention (NCDC) and National Primary Health Care Development Agency (NPHCDA), and international partners, including the University of Washington, University of California San Francisco, and the Institute for Disease Modeling. This research component will focus on monitoring drug safety (Adverse Drug Reactions), antimicrobial resistance, and mortality trends.
The intervention component will however involve a bi-annual (every 6 months) mass administration of azithromycin to children aged 1–59 months and will be implemented by Malaria Consortium alongside other key partners, including Sightsavers, eHealth Africa, African Field Epidemiology Network (AFENET), Mission to Save the Helpless (MiTOSATH), Solina Centre for International Development and Research, World Health Organization (WHO), United Nations International Children's Emergency Fund (UNICEF), and regulatory bodies such as NHREC and NAFDAC.Malaria Consortium is the directly implementing the SARMAAN II project in Kaduna, Kebbi, Jigawa, Gombe and Adamawa states, while providing oversight to AFENET and MiTOSATH to implement in Katsina, Zamfara, Yobe and Bauchi States. Malaria Consortium will explore integrating Maternal, Newborn, and Child Health (MNCH) services into AZM mass administration across implementing states. Where applicable and feasible, services such as MUAC screening, antenatal care (ANC) assessments, and Vitamin A supplementation will be researched and incorporated within the SARMAAN II project.
The primary goal of SARMAAN II is to explore the potential of azithromycin in reducing under-five mortality in Nigeria, where the under-five mortality rate (U5MR) currently stands at 105 deaths per 1,000 live births, and the infant mortality rate (IMR) at 60 deaths per 1,000 live births. By addressing the leading causes of child mortality including respiratory infections, diarrhoea diseases, pneumonia, and malaria, the project aims to contribute to significant reductions in morbidity and hospitalization rates. To achieve measurable impact, the consortium is committed to reaching at least 80% coverage of eligible children across all implementing states during the MDA rounds. To assess the campaigns' impact, relevant indicators, including pneumonia incidence, diarrhea incidence, and malaria positivity rates among others will be routinely monitored.
After the delivery of AZM in each round one of every new year rounds, an End-of-round (EoR) evaluation exercise will be conducted to obtain timely information about the implementation phase. The EoR evaluation will be conducted using the Lots Quality Assurance Sampling (LQAS) methodology which is designed primarily to identify lots (designated supervision areas) that are falling short of agreed quality standards and will offer the opportunity to also measure coverage of delivery.
We are recruiting to fill the position below:
Job Title: Data Collector
Location: Kebbi
Purpose of the assignment
Scope
Methodology
Type of personnel required for the evaluation
Data Collectors/Research Assistants:
Specific Activities for the Data collectors:
Deliverables for Data Collectors:
Profile requirements of data collectors
Application Closing Date
27th July, 2026; before 5:00PM.
How to Apply
Interested and qualified candidates should:
Click here to apply online
Note